A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

1 week ago 40

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Read Entire Article

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Related

Kevin Warsh’s odds of becoming Fed chair leap higher as Dimo...

Walmart was too late for a Nasdaq-100 spot — but these 6 sto...

‘I expected to die’: I claimed Social Security early, but I’...

Trending

Popular

Disney’s deal with YouTube TV shows how streamers are increa...

Warning: WhatsApp worm targets Brazilian crypto wallets, ban...

Why the once-invincible Nvidia can’t save the AI trade

Scaramucci family invested over $100M in Trump’s Bitcoin min...

Is 2025 Worse Than 2022 for Crypto? Nic Carter and McCordic ...

Crypto sentiment index sinks to lowest score since February

Nasdaq ISE Files to Lift BlackRock IBIT Option Limits Into T...

Nvidia earnings have become crucial to the stock market — an...

'Permissionless Assets’: Robinhood’s 3-Phase Tokenization Pl...

Crypto index ETFs will be the next wave of adoption — Wisdom...